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Abstract
Background: The systemic surveillance of imipenem-resistant Acinetobacter baumannii (IRAB) from multicenters in
Taiwan revealed the emergence of isolates with blaOXA-72. This study described their genetic makeup, mechanism of
spread, and contribution to carbapenem resistance.
Methods: Two hundred and ninety-one non-repetitive isolates of A. baumannii were collected from 10 teaching
hospitals from different geographical regions in Taiwan from June 2007 to September 2007. Minimal inhibitory
concentrations (MICs) were determined by agar dilution. Clonality was determined by pulsed-field gel
electrophoresis. Plasmid was extracted and digested by restriction enzymes, and subsequently analyzed by
electrophoresis and Southern blot for blaOXA-72. The flanking regions of blaOXA-72 were determined by inverse PCR.
The contribution of blaOXA-72 to imipenem MIC was determined by transforming plasmids carrying blaOXA-72 into
imipenem-susceptible A. baumannii.
Results: Among 142 IRAB in Taiwan, 27 harbored blaOXA-72; 22 originated from Southern Taiwan, 5 from Central
Taiwan, and none from Northern Taiwan. There were two major clones. The blaOXA-72 was identified in the plasmids of
all isolates. Two genetic structures flanking plasmid-borne blaOXA-72 were identified and shared identical sequences in
certain regions; the one described in previous literature was present in only one isolate, and the new one was present
in the remaining isolates. Introduction of blaOXA-72 resulted in an increase of imipenem MIC in the transformants. The
overexpression of blaOXA-72 mRNA in response to imipenem further supported the contribution of blaOXA-72.
Conclusions: In conclusion, isolates with new plasmid-borne blaOXA-72 were found to be disseminated successfully in
Southern Taiwan. The spread of the resistance gene depended on clonal spread and dissemination of a new plasmid.
BlaOXA-72 in these isolates directly led to their imipenem-resistance.
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Background
Acinetobacter baumannii has become an important
nosocomial pathogen throughout the world because of
its drug resistant phenotype [1]. The resistance to
carbapenems is the most troublesome due to a limited
number of efficacious drugs and the association with poor
prognosis [2]. The mortality associated with imipenem-
resistant A. baumannii (IRAB) is higher than that
caused by susceptible strains, which is attributable to
the higher rate of inappropriate antimicrobial thera-
py [3,4]. Although modification of antibiotic targets,
overexpression of efflux pumps, and loss of porins leads
to carbapenem resistance, the main mechanism in the
Acinetobacter species is production of carbapenemases,
including Ambler class B metallo-β-lactamases and class
D β-lactamases [5]. Compared with other Acinetobacter
species, class D β-lactamases in A. baumannii, including
the intrinsic blaOXA-51-like as well as acquired blaOXA-23-like,
blaOXA-24-like, blaOXA-58-like, and blaOXA-143 genes are more
commonly identified as the cause of resistance [5,6]. The
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distribution of class D β-lactamases varies among coun-
tries, even among regions in the same country [7]. Isolates
with blaOXA-23 spread over a wide geographical range [8],
whereas those carrying blaOXA-24, though relatively less
common, have emerged in France, Italy, South Korea, and
Brazil [9-12]. In Taiwan, one pilot study described the
spread of isolates with blaOXA-72, a member of the blaOXA-24
family, within a single medical center [13]. Thus, in this
study, we collected clinical isolates of A. baumannii from
10 medical centers in different areas in Taiwan during
2007 and found the different geographic distribution of
isolates carrying blaOXA-24/72. Therefore, this multicenter
study aimed to describe their genetic makeup, mechanism
of spread, and contribution to carbapenem resistance in
A. baumannii in Taiwan.
Methods
Bacterial identification and antimicrobial susceptibility testing
Two hundred and ninety-one non-repetitive isolates of
A. baumannii were retrospectively collected from 10
teaching hospitals from different geographical regions in
Taiwan from June 2007 to September 2007. Four hospi-
tals are located in Northern (N1-N4) Taiwan, 3 are lo-
cated in Central (C1-C3) Taiwan, and 3 are located in
Southern (S1-S3) Taiwan (Additional File 1). All isolates
were taken as part of standard patient care and investi-
gators retrospectively collected these isolates. This
microbiological study without patient data was exempt
from full review by our institutional review boards.
All isolates were identified to the species level using a
multiplex PCR method to confirm the specific intergenic
spacer region in A. baumannii [14]. The minimal inhibitory
concentration (MIC) of imipenem, meropenem, ticarcillin,
piperacillin, ceftazidime, cefepime, sulbactam, ciprofloxacin,
and colistin was determined using the agar dilution method
according to the guidelines provided by the Clinical and
Laboratory Standards Institute (CLSI) [15]. The testing and
interpretation were in accordance with the guidelines of CLSI
breakpoints or manufacturer’s instructions. A. baumannii
isolates that were resistant to imipenem were subjected to
the experiments described below.
Identifying Ambler class B metallo-β-lactamases and class
D β-lactamases
PCR methods were used to detect blaOXA-23-like, blaOXA-24-like,
blaOXA-58-like, blaISAba1-OXA51-like, blaOXA-143, blaIMP-like,
blaVIM-like, blaGIM-1, blaSPM-1 and blaSIM-1 as previously
described [6,16,17]. The PCR products were then se-
quenced at Mission Biotech, Taipei, Taiwan. Primers of
ISAba1F and ISAba1R were used to detect the presence of
ISAba1, whereas the ISAba1F and OXA-likeR primers
against the different genes described above were used to
confirm the presence of ISAba1 upstream of the carba-
penemase gene [16].
Determination of clonality by pulsed-field gel
electrophoresis of isolates with blaOXA-72
The clonality of strains with blaOXA-72 was determined
by pulsed-field gel electrophoresis after digestion with
ApaI as previously described [18]. The stained gel was
photographed and analyzed by BioNumerics software
(Applied Maths) to generate a dendrogram of related-
ness among these isolates. Isolates with similarity > 85%
was designated as one clone.
Determination of the plasmid localization of blaOXA-72 by
Southern blot
The plasmid localization of blaOXA-72 was visualized as
previous reported [19]. The plasmid was extracted with
a plasmid DNA Miniprep Kit (Bioman, Taipei, Taiwan)
or a plasmid Maxiprep Kit (Qiagen, Valencia, CA). The
extracts were treated with EcoRI and subjected to elec-
trophoresis. After transfer to the hybridization transfer
membrane (PerkinElmer, Boston, MA) and hybridization
with a PCR-generated probe derived from primers
targeting blaOXA-72 (Additional File 2), the band was visu-
alized with a digoxigenin (DIG) DNA labeling and detec-
tion kit (Roche Diagnostics, Basel, Switzerland) according
to the manufacturer’s instructions.
Sequencing of flanking region of plasmid-borne blaOXA-72
by inverse PCR
Inverse PCR was performed as previously reported [20].
Briefly, the plasmid extracted from isolates carrying
blaOXA-72 was digested with EcoRI, HindIII, or BglII, re-
spectively. After overnight incubation and subsequent
purification, T4 DNA ligase (Promega Corp., Madison,
USA) was added in each extract according to the manu-
facturer’s instructions. Outward amplification with PCR
primers (Additional File 2) covering portions of the
blaOXA-72 region was carried out under standard con-
Table 1 Minimal inhibitory concentrations (MICs) of
antimicrobial agents for Acinetobacter baumannii
carrying blaOXA-72







Imipenem 128 128 100.0%
Meropenem >128 >128 100.0%
Ticarcillin >128 >128 100.0%
Piperacillin >128 >128 100.0%
Ceftazidime >128 >128 100.0%
Cefepime 64 >128 96.3%
Sulbactam 32 32 63.0%
Ciprofloxacin 128 >128 100.0%
Colistin 1 1 0.0%
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Isolates Clonality Hospitals ISAba1-bla OXA-51 
Plasmid carrying 
bla OXA-72 
Flanking regions  
of bla OXA-72 
Positive PCR  
 (primer P1-P2)  
1767 1 S3 - + B - 
1768 1 S3 - + B - 
1759 2 S3 - + B - 
2117 2 S2 - + B - 
1823 A1 M2 - + B - 
1913 A1 M2 - + B - 
1921 A1 M2 - + B - 
1929 A1 M2 - + B - 
1762 A1 S3 - + B - 
1769 A1 S3 - + B - 
1753 A1 S3 - + B - 
1758 A1 S3 - + B - 
1924 A1 M2 - + B - 
1755 A1 S3 - + B - 
2101 A2 S2 - + B - 
2110 A2 S2 - + B - 
2096 A2 S2 - + B - 
2102 A2 S2 - + B - 
2125 A2 S2 - + B - 
2104 A2 S2 - + B - 
1771 A2 S3 - + B - 
2088 A2 S2 - + B - 
2089 A2 S2 - + B - 
2111 A2 S2 - + B - 
2116 A2 S2 - + B - 
1765 3 S3 - + A + 
2093 4 S2 - + B - 
Figure 1 Molecular characteristics of Acinetobacter baumannii carrying blaOXA-72 in Taiwan. The results of pulsed-field gel electrophoresis
are shown, followed by the hospitals of the isolates, pulsotype, presence of ISAba1 upstream of blaOXA-51, localization of blaOXA-72, flanking regions







Figure 2 Electrophoresis (a) and Southern blot (b) of isolates carrying blaOXA-72. The pattern of plasmid electrophoresis and Southern blot
was very similar among isolates. However, Southern blot revealed blaOXA-72 in isolate 1765 (arrow) may be located in a different genetic
background. All isolates were tested but only the results of 15 isolates (from Lane 1 to 15) were presented. M, marker (Bio-1KBTM Mass DNA
Ladder, Protech Technology Enterprise Co., Ltd, Taiwan).
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ditions. The product was then sent for sequencing at
Mission Biotech, Taipei, Taiwan.
Determination of the contribution of blaOXA-72 to
carbapenem MIC
The blaOXA-72 was cloned into the shuttle vector pYMAb2
[21], which carries a kanamycin resistant determinant.
The recombinant plasmid (pYMAb2:: blaOXA-72) and con-
trol plasmid (pYMAb2) were then transformed into the
kanamycin-susceptible Ab290 strain by electroporation
using an gene pulser electroporator (Bio-Rad, Hercules,
CA) and 2 mm electrode gap cuvettes. The antimicrobial
MICs of Ab290 (pYMAb2:: blaOXA-72) and Ab290
(pYMAb2) were determined as previously described [15].
Ab290 was an A. baumannii clinical isolate that was
susceptible to multiple antimicrobial agents from Taipei
Veterans General Hospital and has been used for trans-
formation in the previous study [19]. After incubation
without or with antimicrobial agents, the OXA-72
mRNAs in Ab290 (pYMAb2:: blaOXA-72) were compared
using quantitative PCR [21]. Briefly, bacterial RNA was
extracted using an RNAprotect Bacteria Reagent and
RNeasy mini-kit (Qiagen, Valencia, CA). After elimination
of genomic DNA by RNase-free DNase (Qiagen) treat-
ment, reverse transcription was performed using random
hexamers (Qiagen). Real-time PCR for blaOXA-72 was
carried out with recA as an internal control on an ABI
7500 Fast real-time PCR system (Applied Biosystems, Inc.)
These experiments were performed in at least triplicate.
Results
Bacterial identification and antimicrobial susceptibility
testing
One-hundred and forty-two A. baumannii strains were
resistant to imipenem. Among them, 27 (19.0%) carried
blaOXA-72, including 22 of 38 isolates from Southern
Taiwan (57.9%) and 5 of 62 isolates from Central Taiwan
(8.1%). The number of isolates with blaOXA-72 was sig-
nificantly higher in those obtained from the southern
area than those from other areas (57.9% vs. 4.8%, re-
spectively; P < 0.001 by χ2 test). All of the A. baumannii
isolates carrying blaOXA-72 were resistant to carbape-
nems (Table 1). In addition, they were all multidrug re-
sistant [22], but were susceptible to colistin.
Identifying Ambler class B metallo-β-lactamases and class
D β-lactamases
All isolates with blaOXA-72 had the blaOXA-51-like. The
blaOXA-23-like, blaOXA-58-like, blaOXA-143, blaIMP-like, blaVIM-like,
blaGIM-1, blaSPM-1 and blaSIM-1 genes were not detected by
PCR methods. In addition, ISAba1 was not detected in any
of the strains.
ORF Property Size Identity Accession no.
1 Putative cytoplasmic membrane proteina 384 100 AY739646.1
2 Putative inner membrane proteinb 297 99 AY739646.1
3 XerC/XerD 28 NA AY739646.1
4 BlaOXA-72 828 99 AY739646.1
5 XerD/XerC 28 NA AY739646.1
6 Hypothetical protein 557 99 AY739646.1
7 RepA_AB 888 99 AY739646.1
8 imperfect 4-repeat iteron 95 100 AY739646.1
9 OriV 201 100 AY739646.1
10 RepAci2 576 100 GQ338083.1
11 RepAci1b 242 99 GQ338083.1
a Partial sequence for plasmid A; b Partial sequence for plasmid B
a
b
Figure 3 Schematic map of the partial flanking region of blaOXA-72 in two types of plasmids (plasmid A and B, Figures 3a and 3b,
respectively) in Taiwan. The arrows indicate the predicted open reading frames (ORFs) and their transcriptional directions. The names of various
features are indicated below the map. The sequenced fragment in plasmid A shared 99% similarity to the previously prevalent plasmid (accession
no. AY739646.1), whereas the region downstream of XerD/XerC in plasmid B was identical to another plasmid (accession no. GQ338083.1).
P1 and P2 primers are specific for plasmid A and P3 and P4 primers are specific for plasmid B.
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Determination of clonality by pulsed-field gel electrophoresis
To determine whether emergence of these isolates with
blaOXA-72 was due to clonal spread, pulsed-field gel elec-
trophoresis was performed (Figure 1). Twenty-one iso-
lates (77.8% belonged to 2 major clones (A1 and A2)
(Figure 1). The other six isolates carrying blaOXA-72 (in-
cluding isolate 1765) did not belong to the two major
clones and had only 65-75% homology related to the
major clones. The A1 clone comprised all (5/5, 100%) of
the isolates from Central Taiwan and 5 isolates (5/10,
50.0%) from S3 hospital, whereas the A2 clone com-
prised 10 isolates (10/12, 83.3%) from S2 and 1 isolate
(1/10, 10%) from S3 hospital.
Determination of the plasmid localization of blaOXA-72 by
Southern blot
Electrophoresis showed minor differences in plasmid pat-
terns among isolates (Figure 2). Southern blot using a
blaOXA-72 probe further revealed the presence of blaOXA-72
in the plasmids obtained from 27 isolates. However, South-
ern blot also detected two types of segments flanking
blaOXA-72 after EcoRI digestion. One was present in isolate
1765 and the other was present in the remaining 26 isolates.
Sequencing of the flanking region of plasmid-borne
blaOXA-72 by inverse PCR
Based on the Southern blot results, we anticipated that
there were at least two genetic structures flanking the
blaOXA-72 gene. Inverse PCR of isolate 1765 and randomly
selected isolates revealed two types of genetic structures
flanking the gene (Figures 3a and 3b, fragment A of
3596 bp and B of 2325 bp). An identical 967 bp region
containing blaOXA-72 in both fragment A and B was
flanked by XerC/XerD and XerD/XerC. The 3596 bp frag-
ment A had 99% similarity to pAB02 (GenBank accession
no. AY228470.1) and contained a region with 100% simi-
larity to the plasmids reported from the same teaching
hospital (828 bp, accession no. AY739646.1) [13]. In frag-
ment B, the 1195 bp region upstream of XerD/XerC had
99% similarity to that in fragment A, but the region down-
stream of XerD/XerC was similar to other plasmids with-
out blaOXA-72 (accession no. GQ338083.1), indicating
possible recombination between the plasmids. Using a
specific primer pair (P3 and P4, Additional File 2) for frag-
ment B (Figure 3), the PCR result was positive in 26 iso-
lates, except isolate 1765. The specific primers used to
confirm the presence of fragment A were similar to those
used in a previous study (primers P1 and P2, respectively;
Figure 3) [13]. Only one isolate (isolate 1765) was positive
for fragment A. The mutual exclusion of fragment A and
B indicated that they were located on different plasmids,
designated as plasmid A and B, respectively.
Determination of the contribution of blaOXA-72 to
carbapenem MIC
To determine the contribution of blaOXA-72, A. baumannii
strain Ab290 was transformed with pYMAb2 and
pYMAb2::blaOXA-72, respectively. Compared to Ab290
(pYMAb2), transformation with blaOXA-72 resulted in an
increase in the MICs of imipenem, meropenem, ticarcillin,
sulbactam, and ampicillin (Table 2). We were interested
in determining if the addition of carbapenems would
increase OXA-72 expression. Thus, strain Ab290 (pYMAb2::
blaOXA-72) was treated with ciprofloxacin, imipenem, and
ticarcillin. Quantitative PCR showed that the RNA expres-
sion of the gene increased by 8-fold after addition of
imipenem compared to addition of ciprofloxacin or tic-
arcillin (Figure 4).
Discussion
The resistance rate to carbapenems in A. baumannii has
been increasing worldwide. Ambler class D β-lactamases
Figure 4 Results of quantitative PCR of mRNA levels of OXA-72
in Acinetobacter baumannii carrying blaOXA-72 in response to
different antibiotics. The A. baumannii isolate carrying blaOXA-72 was
treated without antibiotics (Luria-Bertani broth, LB), or with ciprofloxacin
(CIP) at 0.25 mg/L, ticarcillin (TIC) at 1024 mg/L, and imipenem (IMP) at
8 mg/L for 7 hours. Quantitative PCR revealed higher mRNA levels of
OXA-72 in isolates treated with imipenem compared to those treated
with ciprofloxacin or ticarcillin. * P value < 0.05 by one-way analysis of
variance (ANOVA) and by the Scheffe post-hoc method.
Table 2 Minimal inhibitory concentrations (mg/L) of antimicrobial agents for Acinetobacter baumannii with or without
plasmids carrying blaOXA-72
Isolates Imipenem Meropenem Ticarcillin Ampicillin Sulbactam Cefepime Ceftazidime Ciprofloxacin
Ab290 0.25 0.5 8 128 2 2 2 0.5
Ab290 (pAbYM2) 0.25 0.5 8 128 4 2 4 0.25
Ab290 (pAbYM2::blaOXA-72 ) 32 32 >1024 >1024 16 4 4 0.5
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are responsible for the main mechanism of resistance in
A. baumannii. BlaOXA-72, which was first discovered in
Thailand, has since spread rapidly to other areas of Asia
and Europe [9-13]. In this study we collected 142 IRAB
from different geographical regions of Taiwan. Among
them, 27 IRAB carrying blaOXA-72 gene had successfully
spread throughout Southern Taiwan and extended into
Central Taiwan. One new type of plasmid, which har-
bored a different genetic structure compared to that pre-
viously reported, not only existed in the two major
clones, but also disseminated to other clones. We also
found evidence that blaOXA-72 contributed to carbape-
nem resistance. The mRNA levels of OXA-72 increased
in response to the addition of imipenem.
Many studies have demonstrated an association of
carbapenem resistance and the presence of blaOXA-72.
One study [23] revealed that the plasmid carrying
blaOXA-72 modestly increased the MICs of imipenem
and meropenem in Escherichia coli (0.125 to 0.25 and
0.016 to 0.032, respectively). Another study [9] showed
that transformation of susceptible strains with the entire
plasmid carrying blaOXA-72 extracted from clinical iso-
lates resulted in resistance to carbapenems, but not
cephalosporins. However, the increase of carbapenem
MIC might be attributed to other genetic determinants also
present in the transformed plasmid in that study. In our
study, we only cloned the blaOXA-72 gene into the plasmid
without other resistance mechanisms against carbapenems.
The transformation greatly increased the MICs of carbape-
nems (64-128–fold), which was further supported by the
elevated mRNA levels of OXA-72 in response to the
addition of imipenem. Moreover, our study has revealed for
the first time that the transformation also increased the
MICs of ticarcillin, ampicillin, and sulbactam.
The molecular epidemiology of Ambler class D β-
lactamases differs among geographical regions [7]. Our
previous study showed prevalence of blaOXA-23 in Central
Taiwan [24], whereas the current study showed the
blaOXA-72 was mainly disseminated in Southern Taiwan.
Our study revealed that the clonal spread and plasmid dis-
semination were important for blaOXA-72, similar to previ-
ous studies [13,23,25]. The mechanisms of spread of
different carbapenemase genes seemed to be different, as
our previous study showed that a transposon may be the
main reason of spread of blaOXA-23 in Central Taiwan [24].
Lu et al. found that the plasmid carrying blaOXA-72 was
positive for PCR in half of the isolates (49.2%, 29/59) in
one teaching hospital in Southern Taiwan using P1 and P2
primers [13]. Our study recovering isolates from multiple
centers only identified one isolate from the same hospital
assessed in a previous study [13] that may harbor the same
plasmid (plasmid A). This suggests that plasmid A may
have been replaced by plasmid B during this period. Plas-
mid B shared part of the genetic structure with plasmid A.
The shared regions included not only regions between
XerC/XerD binding sites, which were presumed to be re-
sponsible for mobilization of blaOXA-72 [23,25,26], but also
regions upstream from it. This may suggest that these
plasmids have undergone a recombination event.
Conclusions
In conclusion, our study has revealed that the dissemin-
ation of IRAB isolates carrying the blaOXA-72 gene may be
due to clonal spread and dissemination of a new plasmid.
The blaOXA-72 gene contributed to carbapenem resistance.
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